Oncodesign Servicesfeb News Today

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, follow...

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.